New plant expression systems drive vaccine innovation and opportunity

BioProcess International

Volumn 9, Issue 4, 2011, Pages 16-20

  Langer, Eric ^a  

^a BioPlan Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN; VACCINE;

2009 H1N1 INFLUENZA; ANTHRAX; BANANA; CHOLERA; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIARRHEA; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LETTUCE; LICENSING; MAIZE; MALARIA; NOROVIRUS; PLANT BIOTECHNOLOGY; POTATO; RICE; SHORT SURVEY; TOBACCO; TOMATO;

EID: 79955162419     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Rader RA. Biopharmaceutical Expression Systems and Genetic Engineering Technologies: Current and Future Manufacturing Systems. BioPlan Associates, Inc.: Rockville, MD, 2009.
2. Third National Congress on Health System Readiness, 1 December 2009, Washington, DC. American Medical Association: Chicago, IL.
3. Barbeau B. Case Study: Scale-Up of a Transient Plant-Based Expression System. Vaccine Production Summit, 14-16 June 2010, La Jolla, CA. IBC Life Sciences: Westborough, MA, 2010.